---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-219361"
form_type: "8-K"
ticker: "BOLT"
cik: "0001641281"
company_name: "Bolt Biotherapeutics, Inc."
filed_at: "2026-05-12T20:05:16+00:00"
generated_at: "2026-05-12T20:08:56.943461+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026

## Summary
- Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.
- Cash balance of $23.9M as of March 31, 2026; expected to fund operations into 2027, including dose-escalation completion.
- Q1 2026 loss from operations $7.6M vs $12.1M in Q1 2025; R&D expense down to $4.8M from $9.5M.
- Two next-generation ISAC programs (CEA and PD-L1) on hold pending BDC-4182 proof-of-concept.
- Collaboration revenue fell to $26,000 in Q1 2026 from $1.2M in Q1 2025.

## SEC filing metadata
- accession: 0001193125-26-219361
- form_type: 8-K
- ticker: BOLT
- cik: 0001641281
- company_name: Bolt Biotherapeutics, Inc.
- filed_at: 2026-05-12T20:05:16+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/0001193125-26-219361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-219361
- JSON: https://secwatch.observer/filing/0001193125-26-219361.json
- Plain text: https://secwatch.observer/filing/0001193125-26-219361.txt

## Key facts
- Earnings Releases
  Bolt Biotherapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total collaboration revenue was $26,000 for the quarter ended March 31, 2026.
  - Period: first quarter ended March 31, 2026
  - Revenue: Total collaboration revenue was $26,000 for the quarter ended March 31, 2026
  - Result: reported results
  source text: Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/0001193125-26-219361-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.